RecruitingNot ApplicableNCT06337786

Investigating the Effects of the Digital App Rheumabuddy4.1 in a Clinical RCT Set-up in Patients With Rheumatoid Arthritis

A Randomized Controlled Clinical Trial Investigating the Effects of the Digital App Rheumabuddy4.1 in Patients With Rheumatoid Arthritis


Sponsor

Henning Bliddal

Enrollment

70 participants

Start Date

Mar 31, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

Rheumatoid arthritis (RA) is one of the most frequently occurring autoimmune rheumatic diseases, affecting an estimated 1% of the global population. RA is a chronic inflammatory disease that leads to the development of synovial inflammation and effusion, ultimately followed by joint destruction and permanent disability. The substantial socioeconomic burden and the challenge of RA patients adhering to treatment is an important factor of this disease and its impact on both patients and society. An innovative approach is needed in order to find new ways to assist and truly empower patients to understand their disease, increase compliance and thereby increase quality of life. There is a discrepancy in the understanding of what's of importance when living a life with a chronic disease. The importance of patients' perspectives concerning disease- and treatment related impacts, is of crucial importance when involving patients in decisions about treatment, and to support the patients in optimal medication-taking behaviour to ensure patient health and reduce health care costs. There are still unmet needs that have a huge impact on quality of life (QoL) such as fatigue, pain, sleep and psychological issues, etc, which need to be taken seriously as these can have severe and debilitating consequences for the individual. The aim of this study is to investigate and evaluate the effects of the digital app RheumaBuddy4.1 (RB4.1) and the ability to provide support and increase quality of life in patients with RA


Eligibility

Min Age: 18 YearsMax Age: 65 Years

Plain Language Summary

Simplified for easier understanding

This study tests whether using the digital app "Rheumabuddy 4.1" can help people with rheumatoid arthritis (RA) better manage their disease by tracking symptoms, medication, and wellbeing from their phone. **You may be eligible if...** - You are 18 to 64 years old - You have been diagnosed with rheumatoid arthritis (RA) - Your disease activity score (DAS28-CRP) is 3.2 or below (RA is relatively controlled) - Your overall symptom level (PGA) is moderate or higher - You are motivated and able to use a smartphone app **You may NOT be eligible if...** - You have dementia or significant cognitive, language, or physical difficulties - You have vision impairment that prevents using a device or computer - Your RA medication (DMARD) was changed in the past 8 weeks - You have fibromyalgia (widespread chronic pain), active infection, severe asthma, severe COPD, or unstable heart disease - You are currently a smoker or have a fever - You are already receiving intensive physiotherapy, electrostimulation, or motivation training outside of standard care Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICEDigital app RB4.1

Standard care and the digital app RB4.1

OTHERControl arm

Standard care alone


Locations(1)

The Parker Institute, Bispebjerg and Frederiksberg Hospital

Frederiksberg, Copenhagen F, Denmark

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06337786


Related Trials